LeMaitre Vascular (NASDAQ:LMAT) Downgraded to Hold at StockNews.com

StockNews.com lowered shares of LeMaitre Vascular (NASDAQ:LMAT) from a buy rating to a hold rating in a research note issued to investors on Thursday.

LMAT has been the subject of a number of other reports. Barrington Research upped their price target on LeMaitre Vascular from $69.00 to $79.00 and gave the company an outperform rating in a research note on Friday, May 3rd. Roth Mkm reaffirmed a buy rating and set a $100.00 price target on shares of LeMaitre Vascular in a research note on Friday, May 31st. Stifel Nicolaus raised shares of LeMaitre Vascular from a hold rating to a buy rating and raised their price target for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. JMP Securities increased their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the company a market outperform rating in a report on Friday, May 3rd. Finally, Roth Capital raised LeMaitre Vascular to a strong-buy rating in a report on Friday, May 31st. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, LeMaitre Vascular presently has an average rating of Moderate Buy and an average price target of $77.57.

LeMaitre Vascular Stock Down 4.5 %

Shares of NASDAQ LMAT opened at $86.24 on Thursday. The firm’s 50-day simple moving average is $81.83 and its 200 day simple moving average is $70.39. The company has a market cap of $1.94 billion, a price-to-earnings ratio of 57.11, a price-to-earnings-growth ratio of 2.75 and a beta of 0.89. LeMaitre Vascular has a 12-month low of $44.27 and a 12-month high of $91.76.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The company had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. During the same period in the prior year, the company posted $0.27 EPS. The company’s revenue was up 13.6% compared to the same quarter last year. On average, equities analysts expect that LeMaitre Vascular will post 1.77 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, May 30th. Investors of record on Thursday, May 16th were given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date of this dividend was Wednesday, May 15th. LeMaitre Vascular’s payout ratio is currently 42.38%.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 68,906 shares of the business’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the completion of the transaction, the chief executive officer now owns 2,133,428 shares of the company’s stock, valued at $161,500,499.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CEO George W. Lemaitre sold 27,030 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the sale, the chief executive officer now directly owns 1,958,328 shares in the company, valued at $168,944,956.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO George W. Lemaitre sold 68,906 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $75.70, for a total value of $5,216,184.20. Following the transaction, the chief executive officer now owns 2,133,428 shares in the company, valued at $161,500,499.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 127,437 shares of company stock worth $10,076,242. Company insiders own 10.79% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently modified their holdings of the business. Shaker Investments LLC OH raised its position in shares of LeMaitre Vascular by 1.3% during the second quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier’s stock worth $1,138,000 after purchasing an additional 175 shares during the period. Bank of New York Mellon Corp increased its position in shares of LeMaitre Vascular by 2.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 210,599 shares of the medical instruments supplier’s stock valued at $17,328,000 after purchasing an additional 5,213 shares during the last quarter. West Oak Capital LLC purchased a new stake in shares of LeMaitre Vascular during the 2nd quarter valued at $58,000. Louisiana State Employees Retirement System increased its position in shares of LeMaitre Vascular by 3.1% during the 2nd quarter. Louisiana State Employees Retirement System now owns 10,100 shares of the medical instruments supplier’s stock valued at $831,000 after purchasing an additional 300 shares during the last quarter. Finally, Fifth Third Bancorp increased its position in shares of LeMaitre Vascular by 6.6% during the 2nd quarter. Fifth Third Bancorp now owns 10,888 shares of the medical instruments supplier’s stock valued at $896,000 after purchasing an additional 678 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.